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ABSTRACT
 In normal cells cluster of differentiation 74 (CD74) acts as a chaperone of human leukocyte antigen (HLA)-DR
 by formation of a trimetric structure. In the lack of tumor presence most antigen presenting cells are expressed.
 However, recent data suggests that CD74 is major link between proinflammatory responses and tumorigenesis
 but that detailed mechanisms are not fully understood. CD74 is also thought to be involved in signalling pathways
 via macrophage migration inhibitory factor (MIF) and CD44; controlling the proliferation and apoptosis of cancer
 its capability to interact with other signaling cells. The role CD74 as an accessory signal receptor on surface and
 molecules presents CD74 as a crucial therapeutic target for the treatment of cancer. This review will discuss the role
 of CD74 in several aspects including antigen presentation, cancer immunomodulation as well as the interaction of
CD74 along with MIF and CD44.
 The overall aim of this review is to translate the recent outcome from the previous study to the clinical level and to
 study the expression and the role of CD74 in human breast cancer in Saudi population. Comparison between normal
 people and patients could be applied. We are also planning to link the level of CD74 expression to different stage
 of breast cancer so CD74 could potentially be used as a ‘biomarker signature’ to monitor different stages of breast
cancer.
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INTRODUCTION
Structure of cluster of differentiation 74
 In humans, the gene that encodes the CD74
 or invariant chain (Ii) molecule is located on
 chromosome 5q32 (Yamamoto, 1985; Liu
 and Lin, 2014). Jones and his colleagues were
 the first to recognize the Ii protein in 1979,
 specifically when the MHC class α chain and
 Ii was separated in 2D-gels. In spite of this, in
 1989 it was discovered that Ii has a vital role
 in antigen presentation through persuading
 the expression and peptide loading of MHC
 class II molecules (Badve et al., 2002). In
 1995, the name CD74 was given to Ii by
 ‘Leukocyte Typing Workshop’ (Landsverk
 et al., 2009). CD74, also known as invariant
 chain, Ii or MIF receptor, is classified as a
 type II transmembrane glycoprotein that is
 expressed on antigen presenting cells and
 has diverse immunological functions (Burton
 et al., 2004; Stein et al., 2007; Beswick and
 Reyes, 2009). CD74 is post-translationally
 glycosylated and exists in various isoforms.
 There are four isoforms of CD74 in human
 beings, P33, P35, P41 and P43. Via alternative
 splicing of the invariant chain (Ii) transcript
 where the P41 isoform has an extra exon,
 (exon 6b) these isoforms can be differentiated.
 However, the most common isoform (P33)
 has a molecular weight of 33 kDa (Landsverk
 et al., 2009; Beswick and Reyes, 2009).
 The structure of CD74 (shown in Figure 1)
 consists of a short an NH2-terminal cytosolic
 tail of 30 amino acids, intracytoplasmic
 residues (IC), a 26 amino acid hydrophobic
 transmembrane region (TM) and 160 amino
 acid extracytoplasmic domain containing
 two N-linked carbohydrate chains (EC)
 (Stein et al., 2007; Landsverk et al., 2009;
 Shachar and Haran 2011; Gil- Yarom et al.,
 2014). CD74 is synthesized on the rough
 endoplasmic reticulum in same manner as
 MHC class II molecules despite the genes of
 these molecules being located on different
chromosomes (Badve et al., 2002).
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Figure 1: Schematic diagram of gene and protein structure of CD74.
 The corresponding gene of the invariant
 chain (Ii) consists of nine exons. The p33
 and p35 forms of Ii, both encoded by eight
 exons, differ by 16 N-terminal residues as
 a result of alternative translation initiation.
 The p41, encoded by nine exons, is generated
 by alternative splicing of a common pre-
 m-RNA. The exon 6b in p41 and p43 encodes
 a cysteine rich stretch of 64 amino acids
 near the C-terminus. All isoforms contain
 at least two N-linked and two O-linked
 glycosylations. Adapted from (Strubin et al.,
1986, Gregers et al., 2003).
The function of CD74
 The most well-known function of CD74 is its
 ability to associate with MHC class II α and
 β chains, directing the transport of the αβIi
 complex to the endosome and lysosome (Pyrz
 et al., 2010). Specifically, the role of CD74
 in antigen presentation has been divided
 into three main functions. Firstly, CD74
 acts as a chaperone that is responsible for
 stabilizing nascent human leukocyte antigen
 (HLA)-DR αβ-heterodimers by formation of
 a trimetric structure. Secondly, by means of
 various sorting and internalization signals
 in its N-terminal cytoplasmic tail, CD74
 targets HLA-DR molecules to subcellular
 compartments. Thirdly, CD74 prevents
 loading of antigenic peptides into the groove
of HLA-DR molecules outside endosomes/
 lysosomes through a stretch called CLIP
 (Class II-associated Invariant chain Peptide)
 (amino acids 91-99) (Moldenhauer et al.,
 1999). CD74 is evolving as a more effectual
 molecule beside its eminent functions
 of regulating class II MHC trafficking.
Numerous studies have elaborated that cell-
 surface expression of CD74 is not always
 reliant on class II MHC (Wilson et al., 1993;
 Beswick and Reyes, 2009). In this context,
 CD74 has been suggested to function as a
 cytokine and bacterial receptor. CD74 has
 also been shown to be involved in signalling
 along with Macrophage migration inhibitory
 factor (MIF) and CD44 pathways as a survival
 receptor (Stein et al., 2007; Beswick and
 Reyes, 2009). CD74 was also demonstrated
 to be involved in the maturation of B cells
 through a pathway involving nuclear factor
 kappa-light-chain-enhancer of activated B
cells (NF-kB) (Stein et al., 2007).
CD74 and the antigen presentation 
process
The MHC class II molecule is mainly 
expressed by a limited set of cells called 
professional antigen presenting cells (APCs), 
which include cells of the monocyte-
macrophage lineage, dendritic cells (DCs) 
and B-lymphocytes, unlike MHC class I 
molecules which are ubiquitously expressed 
on all nucleated cells (Neefjes et al., 2011). 
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The function of MHC class II is to present 
antigenic peptides from exogenous origin to 
a specialized T cell, CD4+ in the presence 
of invariant chain (CD74). Hence, when 
CD74 is synthesized, it begins to associate 
with MHC class II (HLA-DR-a) and MHC 
class II (HLA-DR-b) within the endoplasmic 
reticulum (Burton et al., 2004; Stein et al., 
2007; Landsverk et al., 2009). The association 
between these molecules is believed to take 
place in the rough endoplasmic reticulum 
through the sequential addition of DR a and 
b  heterodimers to a trimeric core of CD74 
molecules in order to from a nine-subunit 
complex with an equimolar amount of 
CD74–MHC class II. The resulting complex 
of CD74 and MHC class II is then gradually 
transported through Golgi apertures to the 
late endosomal compartment that is termed 
the MHC class II compartment (MIIC) either 
directly or within the plasma membrane. 
Here, CD74 is digested and cleaved into 
peptide fragments by endosomal/lysosomal 
proteases, leaving residual class II-associated 
Ii peptides (CLIP; amino acids 91-99) in the 
peptide-binding groove of the MHC class 
II heterodimer. In order to promote the 
exchange of CLIP fragments for specific 
peptides derived from a protein degraded 
in the endosomal pathway, MHC class II 
molecules require HLA-DM. By reaching 
this stage, MHC class II molecules are ready 
for transporting via the plasma membrane to 
present their peptides to CD4+ T cells (Burton 
et al., 2004; Stein et al., 2007; Landsverk et 
al., 2009; Beswick and Reyes, 2009; Neefjes 
et al., 2011).
The role of CD74 in cancer
The CD74 expression has been reported in 
normal tissues and their associated cells such 
as HLA class II-positive cells, which include 
number of cell types including macrophages, 
dendritic cells, monocytes, B cells, activated 
T cells subsets, cells from thymic epithelium. 
However, several studies have confirmed that 
CD74 is highly expressed in inflammatory 
disorders and several types of tumors (Stein 
et al., 2007; Beswick and Reyes, 2009). For 
example, 90% of B-cell cancers and majority 
of the cell lines derived from these cancers 
express CD74 in high levels compared to 
normal tissues (Stein et al., 2007). In particular, 
CD74 is expressed on different cancer cells, 
such as myeloma; prostate cancer cells, 
cancers of the gastrointestinal tract as well 
as breast cancer (Beswick and Reyes, 2009; 
Verjans et al., 2009). CD74 expression has 
also been shown to be correlated positively 
with gastric cancer stages (Zheng et al., 
2012). Recently, CD74 has been classified 
as a new prognostic factor for patients with 
malignant pleural mesothelioma (Otterstrom 
et al., 2014). Moreover, Cheng et al. (2015) 
have also revealed that CD74 has a high 
potential in treating thyroid carcinoma.
Verjans et al (2009) have shown that breast 
cancer tissues and breast cancer cell lines 
overexpressed CD74. Interestingly, it is also 
reported that CD74 was expressed in tumour 
cells from 61% of ER–/PR– breast cancer 
biopsies and from 33% of ER+/PR+ biopsies 
(Leth-Larsen et al., 2009). Greenwood et al. 
(2011) also revealed that triple negative breast 
cancer highly expressed signal transducer 
and activator of transcription (STAT-1) and 
CD74. Similarly, Tian et al. (2012) have 
shown that CD74 was lower expressed in 
non-triple negative breast cancer while it is 
highly expressed on triple negative breast 
cancer and metastatic lymph nodes. Richard 
et al. (2014) showed that in the absence of 
estrogen receptors, expression of stromal 
CD74 is well associated with triple-negative 
receptor. Recently, according to Yaprak et al. 
(2015) patients who suffer from breast cancer 
with no CD74 expression had significantly 
better surgical outcomes than CD74-
positive. To emphasize the role of CD74 in 
tumourigenicity and immunogenicity, the 
expression of CD74 has been assessed under 
inflammatory conditions using interferon-
gamma and lipopolysaccharide (Greenwood 
et al., 2011; Zheng et al., 2012). Since then 
CD74 has been identified as a potential novel 
target for breast cancer therapies as well as 
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other types of cancer such as prostate, gastric 
cancer and thyroid carcinoma (Meyer-Siegler 
et al., 2004; 2006; Leth-Larsen et al., 2009; 
Verjans et al., 2009; Tian et al., 2012; Zheng 
et al., 2012; Richard et al., 2014; Cheng et 
al., 2015). Gai et al. 2018 have shown that 
the levels of proliferation and invasion were 
decreased in the CD74 knockdown‑HT‑1376 
cells.
CD74 and IFNg
 In terms of proinflammatory cytokines,
 Möller and Moldenhauer (1999) have
 shown that the expression of CD74 can be
 induced using several types of cytokines
 such as IFN-γ, TNF-a and IL-4. Maubach
 et al. (2007) revealed that CD74 expression
 was upregulated when hepatic stellate cells
 (HSCs) were treated with IFN-γ for 30 hr.
 Martín-Ventura et al. (2009) demonstrated
 that the expression of CD74 increased after
 IFN-γ treatment in  human aortic VSMCs
 and THP-1  cells. Moldenhauer et al. (1999)
 also showed that the expression of CD74,
 HLA-DR and HLA-A, B, C increased when
 colon carcinoma cell lines (HT-29 cells)
 were incubated with recombinant- IFN-γ
 (rIFN-γ). Similarly, Burton et al. (2010)
found that CD 74 expression was up-
 regulated not only on the surface of cells
 obtained from acute myeloid leukaemia
 (AML) but also in the tissues from AML
 patients when treated with IFN-γ. In the same
 manner, Greenwood et al. (2011) recently
 demonstrated that the expression of CD74
 is upregulated in breast cancer cell lines.
 Their findings suggested that overexpression
 of CD74 using IFN-γ treatment increased
 adhesion of tumour cells (Greenwood et al.,
 2011). Interferon-gamma (IFN-γ) is a potent
 proinflammatory cytokine that has many
 critical roles including; promoting immune
 responses, immunopathological processes,
 cell maturation, differentiation, activation,
 and apoptosis (Pestka et al., 1987; Platt and
 Hunt, 1998; Dranoff, 2004). It is know that
 IFN-γ plays a critical role in cancer and
 cancer progression by controlling apoptosis,
 cell proliferation, angiogenesis and the
 expression of MHC class I and II (Sikora
 and Smedley, 1983; Gooch et al., 2000;
 Brandacher et al., 2006; Zaidi and Merlino,
 2011;). However, IFN-γ has another face
 that functions against the immune system,
 and increases the tumourigenicity of tumour
 cells (Zaidi and Merlino, 2011). There is
 now emerging evidence that IFN-γ may
also be involved at the equilibrium and/
 or evasion stages, roles that may be more
 pro-tumourigenic. IFN-γ has been shown
 to upregulate the suppression of cytotoxic
 cells (CTL) and NK cell- mediated immune
 responses, and is central to tumour immune
 escape (Brody et al., 2009). IFN-γ has also
 been suggested to enable tumours to escape
 innate immune system surveillance and
 influence tumour growth and dissemination
 by induction of CD74 (Greenwood et al.,
2011; Chao et al., 2012).
The role of CD74 in cancer 
immunomodulation
Research has shown that CD74 plays a 
significant role in tumour immunosurveillance 
and cancer immunomodulation. Chao et al. 
(2012) hypothesised that over expressed 
CD74 might enable tumours to escape 
the immunosurveillance recognition via 
evasion of phagocytosis. It is believed that 
CD74 inhibits phagocytosis via the ligation 
of expressed signal regulatory protein-α 
(SIRP-a) by phagocytes resulting in tyrosine 
activation as well as inhibition of myosin 
accumulation at the submembrane assembly 
site of the phagocytic synapse (Tsai and 
Discher, 2008). So, CD74 functions as a 
‘don’t eat me signal’ and a marker of self, 
as loss of CD74 may lead to phagocytosis of 
damaged cells (Oldenborg et al., 2000; Blazar 
et al., 2001; Chao et al., 2012). This process 
occurs when CD74 on tumour cells binds to 
SIRP-a on phagocytes leading to promotion 
of phagocyte inhibition and tumour survival 
(Chao et al., 2012). In support of this 
hypothesis, it has been shown that forced 
expression of CD74 enhances dissemination 
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and fulminantes death in xenografted mice 
in a CD74-deficient myeloid leukaemia cell 
lines (Jaiswal et al., 2009).
CD74 expression by tumour cells has been 
linked to the process of tumour recognition 
by T cells and antigen presentation (Beswick 
and Reyes, 2009). CD74 is thought to be a 
link molecule between the endogenous and 
the exogenous antigen presentation pathway 
as shown recently by Basha and his group 
(Basha et al., 2012).  It has been also shown 
that CD74 exhibits physical association with 
HLA-DR promoting re-cycling of HLA-DR 
into the endosomes. It was proposed that the 
high level expression of CD74 might prevent 
the antigen presentation process by blocking 
the peptide binding cleft rendering tumours 
less immunogenic. Moreover, it has been 
demonstrated that upregulation of CD74 
in human cancer cells directly influences 
tumours growth and dissemination suggesting 
that CD74 may have a role in escaping the 
equilibrium phase of cancer immuneediting 
(Chao et al., 2012).
 In addition, it has been confirmed recently
 that blocking CD74 expression on tumour
 cells by anti-CD74 antibodies may facilitate
 the elimination of tumour cells by the immune
 system (Zheng et al., 2012; Otterstrom et al.,
 2014). It has been suggested that the anti-CD74
 antibody eradicates tumour cells through
 the Fc-dependent mechanism including
 complement dependent cytotoxicity (CDC)
 and antibody-dependent cellular cytotoxicity
 (ADCC) (Chao et al., 2012). Interestingly,
 it was found that the anti-CD74 antibody
 induces cytotoxicity of NK cells against
 head and neck cancer (Kim et al., 2008).
 Another suggestion proposed is that blocking
 CD74 may induce the level of tumour cells
 apoptosis in vivo and in vitro (Kikuchi et al.,
2005; Uno et al., 2007). Anti-CD74 antibody-
 mediated apoptosis may be involved in
 the ligation process with thrombospondin
 ligand activation but is not dependent on the
 caspase apoptotic pathways (Mateo et al.,
 2002; Manna and Frazier, 2004). In support
 of this finding, CD74 has been suggested to
 be involved in signalling pathways via MIF
 and CD44 increasing tumour cell survival
 and inhibition of apoptosis (Tillmann et al.,
 2013; Yaddanapudi et al., 2013; Richard et
al., 2014).
The interaction of CD74 along with MIF 
and CD44
 Several studies have shown that MIF can
 bind to the extracellular domain of CD74
 to promote signalling pathways including
 inflammatory processes, activation of
 Extracellular-signal-regulated kinases 1
 (ERK1) and Extracellular-signal-regulated
 kinases 2 (ERK2) members of the family of
 mitogen-activated protein kinases (MAPKs),
 cell proliferation, prostaglandin E2 (PGE2)
 production, chemokine-mediated signalling
 and apoptosis (Leng et al., 2003; Shi et al.,
 2006; Starlets et al., 2006; Bach et al., 2009;
 Fan et al., 2011; Tillmann et al., 2013).
 However, the short cytoplasmic tail of CD74
 lacks a signal-transducing intracellular
 domain, although phosphorylation of the
 serine residues takes place on the P35 variant
 of CD74 and requires CD44 (Zernecke et
 al., 2008; Borghese and Clanchy, 2011). The
 binding of CD44 required MIF mediated cell
 signaling cascade via Src-tyrosine kinase
 (Shi et al., 2006) and this also involved
 chondroitin sulfate, which leads to the
 formation of receptor complex that activate
 ERK1 and ERK2 kinases, which further
 activates number of inflammatory mediators
 associated events (Borghese and Clanchy,
 2011; Naujokas et al., 1993). Interestingly,
 the extracellular kinases ERK1 and ERK2
 remain to be activated for several hours.
 Therefore, this cell signaling event continues
 to promote inflammatory process (Mitchell
 et al., 1999; Lue et al., 2006). Not only
 have these, Activation of the kinase (Akt)
 another proinflammatory cell signaling
 pathway is activated by MIF (Lue et al.,
 2007). This further activates pro- apoptotic
 proteins, namely BAD and BAX and the
 cells acquire signals to withstand apoptosis
 (Lue et al., 2007). In B-lymphocytes, MIF
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 induces a signalling cascade that leads to
 NF-κB activation, proliferation and survival
 (Matza et al., 2001; Starlets et al., 2006).
 We have shown recently that CD44 interacts
 only with p41, the most abundant isoform of
 CD74 (Al Ssadh et al., 2017). Unpublished
 data also have confirmed that using siRNA
 to knockdown CD74 in breast cancer might
 play a significant role in the apoptosis and
 proliferation of breast cancer (Al Ssadh
 Hussain, unpublished data). It has been also
 shown recently that CD74 expression is
associated with better prognosis in Basal-
 like subtype invasive breast cancer. This
 association correlates with higher levels of
 MHCII expression by tumor cells and with a
dense TIL response (Wang et al., 2017).
CONCLUSION
The discovery of CD74 and its natural 
ligand as well as its role in association with 
its binding partners has led to understand 
the association of CD74 signaling with the 
molecular mechanisms present in immunity 
and cancer. The expression of CD74 in antigen 
presenting cells is responsible to regulate the 
process of antigen presentation in presence 
of MHC class II. However, recent data has 
shown that CD74 expression may lead to 
incapacitate the immune system. In addition, 
various studies including clinical studies 
revealed that CD74 has a crucial contribution 
in various diseases and different variety of 
cancers. Additional researches on CD74 
along with its effect on cellular processes, 
comprising the complex interactions in 
between CD74 and its binding associates 
such MIF and CD74, will unquestionably 
translate into clinical benefit for patients. 
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دور جزيئات التمايز الخلوي 47 في الأورام ال�سرطانية والتنظيم المناعي لل�سرطان
حسين محفوظ الساده(1)  و وليد بن إبراهيم العبدالمنعم(2) و نيلسون فرنانديز(1)
(1) كلية العلوم الحيوية، جامعة إيسكس، المملكة المتحدة
(2) قسم علم الأمراض، كلية الطب، جامعة القصيم، بريدة، المملكة العربية السعودية
استلام 92 مارس 8102م - قبول 21 يوليو 8102م
الملخص
تم مؤخرا التعرف على الدور التعبيري لجزيئات التمايز الخلوي (47)، حيث تم إثبات تواجدها في عدة أنواع من الخلايا السرطانية وتم 
إثبات دورها للتعرف على تكون الأورام السرطانية في جسم الإنسان. وقد أظهرت دراسة حديثة أيضا أنه قد تم التعبير عن تواجد هذه 
المؤشرات الحيوية بشكل واضح في العديد من الأورام السرطانية مثل سرطان البروستاتا والأورام اللمفاوية نوع بي وسرطان الصدر 
والمعدة. وذلك من خلال ارتباط الجزء الخارجي للمؤشر الحيوي (47) الموجود على سطح الخلية مع بروتين (إم آي إف) لتبدأ عملية 
نقل الإشارات بالخلية. بعد هذه الخطوة تبدأ سلسلة من الإشارات الحيوية المتتابعة بالخلية، ولكن الجزء الداخلي للمؤشر الحيوي (47) 
له القدرة على تثبيط السلسلة التفاعلية مبدئيا بارتباط الذيل القصير للجزء الداخلي للخلية، وهذه العملية تحتاج إلى تواجد المؤشر الحيوي 
(سي دي 44) وهو بروتين غشائي متعدد الأشكال مسؤول عن تفعيل لإنزيم الكاينيز لتتم عملية الفسفرة. وهذا العملية معقدة وتحتاج إلى 
الارتباط مع بروتين (إم آي إف) المسؤول عن تنظيم المحفزات (إي آر كي 1 و إي آر كي 2) ومن ثم بدء تنشيط عدة بروتينات مهمة في 
حالة التهاب الخلية إو إصابتها بعوامل تؤدي بها إلى الموت. فلهذا ركز هذا المقال العلمي على دور جزيئات التمايز الخلوي (47) في مناعية 
الجسم للأورام وكذلك ترابطها مع المؤشر الحيوي (44) وكذلك مع بروتين (إم آي إف). 
الكلمات المفتاحية: الإنتيفيرون غاما، سي دي، عديد السكاريد الشحمي، عرض المستضد للخلايا، مناعية الجسم للأورام.
